细胞因子诱导杀伤细胞联合多西他赛、卡铂治疗晚期卵巢癌的疗效及安全性

发布时间：2018-07-08 09:22

本文选题：卵巢肿瘤 + 化学疗法　；参考：《山东医药》2015年05期

【摘要】：目的探讨细胞因子诱导的杀伤细胞(CIK)联合TC(多西他赛+卡铂)方案治疗晚期卵巢癌的疗效及安全性。方法将91例晚期卵巢癌患者随机分为治疗组46例和对照组45例,治疗组采用TC方案化疗联合CIK治疗,对照组采用TC方案化疗。观察两组近期疗效、免疫功能变化、生活质量改善、生存率及不良反应。结果治疗组的完全缓解率和客观有效率分别为47.8%和87.0%;对照组分别为42.2%和77.8%,两组比较无统计学差异(P均0.05)。治疗组治疗后T细胞亚群中的CD+3、CD+4、CD+16CD+56及CD+4/CD+8均不同程度升高(P均0.05),对照组治疗前后无明显变化(P均0.05)。治疗组76.1%的患者生活质量改善,高于对照组的44.4%(P0.05)。治疗组和对照组的1年生存率分别为81.4%和61.0%,2年生存率分别为62.8%和41.6%,两组比较均有统计学差异(P均0.05)。两组不良反应主要为骨髓抑制、胃肠道反应,两组不良反应发生率比较无统计学差异(P0.05)。结论 CIK联合TC方案治疗晚期卵巢癌安全有效,可以提高患者生活质量及机体免疫力,延长生存期。
[Abstract]:Objective to evaluate the efficacy and safety of cytokine induced killer cell (CIK) combined with docetabine (docetabine) in the treatment of advanced ovarian cancer. Methods 91 patients with advanced ovarian cancer were randomly divided into treatment group (n = 46) and control group (n = 45). The short-term curative effect, immune function change, quality of life improvement, survival rate and adverse reaction were observed. Results the complete remission rate and the objective effective rate were 47.8% and 87.0% in the treatment group and 42.2% and 77.8% in the control group, respectively. There was no significant difference between the two groups (P 0.05). In the treatment group, the CD3 CD4CD4, CD16, CD56 and CD4 / CD8 in T cell subsets were increased in varying degrees (P 0.05), but there were no significant changes before and after treatment in the control group (P 0.05). 76. 1% of the patients in the treatment group improved their quality of life, which was higher than that in the control group (44. 4%) (P0.05). The 1-year survival rate was 81.4% in the treatment group and 61.0% in the control group, and the 2-year survival rate was 62.8% and 41.6, respectively. There was significant difference between the two groups (P 0.05). The main adverse reactions between the two groups were myelosuppression and gastrointestinal tract reaction. There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion CIK combined with TC regimen is safe and effective in the treatment of advanced ovarian cancer.
【作者单位】：邯郸市第一医院;
【分类号】：R737.31

【参考文献】